Search
Now showing items 21-30 of 37
“INCORPORACIÓN DEL BIOMARCADOR ALFA-FETOPROTEÍNA COMO CRITERIO DE SELECCIÓN PARA TRASPLANTE HEPÁTICO POR HEPATOCARCINOMA”.
(2020)
El trasplante hepático es una de las terapéuticas curativas en pacientes con
hepatocarcinoma (HCC) o carcinoma hepatocelular. Sin embargo, la
recurrencia post trasplante hepático es un evento temible, con pobre sobrevida ...
Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission
(Elsevier, 2021-03)
Abstract
Introduction & objectives: The independent effect of liver biochemistries as a prognostic factor in patients with COVID-19 has not been completely addressed. We aimed to evaluate the prognostic value of abnormal ...
Liver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region
(Wiley, 2021-01)
Abstract
This study aimed to compare liver transplantation (LT) outcomes and evaluate the potential rise in numbers of LT candidates with hepatocellular carcinoma (HCC) of different allocation policies in a high waitlist ...
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
(Elsevier, 2021-06)
Abstract
Background & aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated ...
Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort
(Wiley, 2021-04)
Abstract
Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been ...
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection
(Wiley, 2021-02)
Comment J Viral Hepat
. 2021 Feb;28(2):446-447. doi: 10.1111/jvh.13433. Epub 2020 Nov 18.
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection
Ezequiel Ridruejo 1 2 3, Federico Piñero 2 ...
LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study
(Elsevier, 2020-11)
Abstract
Introduction and objectives: The liver imaging reporting data system (LI-RADS) for hepatocellular carcinoma (HCC) was proposed to standardize and enhance consensus of reporting. However, clinical utility of LI-RADS ...
Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma
(Elsevier, 2020-10)
Abstract
The A.A.E.E.H has developed this guideline for the best care of patients with hepatocellular carcinoma (HCC) from Argentina. It was done from May 2018 to March 2020. Specific clinical research questions were ...
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection
(Springer, 2021-11)
Abstract
Introduction and objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized ...
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study
(Wiley, 2021-12)
Abstract
Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared with best ...